Goodwill Pharma Nyrt.
BBUD:GWPH540.00
HUF
0.00
(0.00%)
ISIN
HU0000199575
Return %
Stock
S&P 500
1Y
184.21
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Jójárt Ferenc
- Full Time Employees
- 319
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Szeged Hungary
- Website
- goodwillpharma.com
- Similar Companies
- Business
- Goodwill Pharma Nyrt. is a Hungary-based vertically integrated pharmaceutical and healthcare company engaged in the research, development, manufacturing, marketing, and distribution of pharmaceutical products, dietary supplements, and medical devices. Founded in 1997 and headquartered in Szeged, Hungary, the company operates across Central and Eastern Europe, serving retail pharmacies, healthcare providers, hospitals, and commercial partners. The company conducts business through proprietary pharmaceutical manufacturing, consumer healthcare, third-party contract manufacturing, and commercial distribution services. Its product portfolio includes prescription (Rx) pharmaceuticals and branded generic medicines across therapeutic areas including rheumatology, neurology, gastroenterology, infectious diseases, orthopedics, urology, immunology, and psychiatry; over-the-counter (OTC) preparations for pain management, respiratory conditions, and digestive care; dietary supplements and medical nutrition products, prominently anchored by the flagship Szent-Györgyi Albert vitamin and mineral product family; and specialized medical devices. In addition to proprietary products, the company offers business-to-business services including Good Manufacturing Practice (GMP)-compliant contract manufacturing; primary and secondary packaging; European Union batch release and analytical testing; regulatory registration and dossier management; medical promotion and marketing; and temperature-controlled pharmaceutical logistics and warehousing. The company maintains operational facilities in Szeged, Hungary, and an operating subsidiary with production capabilities in Subotica, Serbia. In recent strategic developments, Goodwill Pharma expanded its capital market presence by listing its ordinary shares on the Standard Market of the Budapest Stock Exchange under the ticker GWPH in April 2025, following a private placement that secured HUF 1.3 billion in growth capital. The company also executed a strategic transaction with STADA Arzneimittel AG, divesting regional distribution rights for its Fortacell brand across six Balkan countries to fund continued international commercial expansion and infrastructure investments. Operationally, Goodwill Pharma completed a major infrastructure expansion in Szeged, establishing the Goodwill Pharma Campus with upgraded GMP manufacturing capacity, advanced research and development laboratories, and expanded pharmaceutical storage capacity for up to 5,000 pallets.